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Spinocerebellar ataxia (SCA) is a neurodegenerative disorder caused by dysfunction
of the cerebellum and its connected neural networks. There is currently no cure
for SCA and symptomatic treatment remains limited. We aimed here to examine
the effects of a repetitive transcranial magnetic stimulation (rTMS) targeting the
cerebellum on clinical impression, postural control and gait in patients with SCA. In
this randomized, double-blinded and sham-controlled study, 20 individuals aged 18–75
years with SCA confirmed by genetic testing completed rTMS or sham intervention
comprising 20 sessions of MRI-guided stimulation over the cerebellum. Baseline
assessments included the Standard Ataxia Rating Assessment (SARA), the 9-hole peg
test of manual dexterity, the Timed Up-and-Go (TUG) test, standing postural control
with eyes-open and eyes-closed, and gait. Immediate (within 1-week) and 1-month
follow-ups were completed. Intervention compliance was high (19 ± 2 of 20 sessions)
and no rTMS-related adverse events were reported. rTMS, compared to sham, was
associated with greater percent improvement in SARA total score from baseline to the
1-month follow-up (p = 0.008). Secondary analyses of individual SARA items revealed
that rTMS improved performance within the “stance” sub-score only (p = 0.002). This
functional change was accompanied by improvement to several objective metrics of
postural sway during eyes-open and eyes-closed standing (p < 0.008). rTMS did not
influence the 9-hole peg test, TUG, or gait kinematics. A 20-session rTMS intervention
is safe and feasible for those with SCA. Additional research is warranted to confirm the
observed longer-term benefits of this intervention on standing postural control.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT01975909
Keywords: rTMS, spinocerebellar ataxia, cerebellum, Standard Ataxia Rating Assessment, standing postural
control
INTRODUCTION
Autosomal dominant spinocerebellar ataxia (SCA) is associated with degeneration of the
cerebellum and its efferent and/or afferent cerebello-thalamocortical tracts (1, 2). Patient with
SCA often present with a host of motor symptoms, including deficits to the control of both
standing posture and gait (3–5). Such deficits are progressive in nature and greatly increase one’s
risk of falling (6, 7) and losing functional independence (8). There is currently no cure for SCA
and attempts to improve the clinical symptoms of ataxia have been largely unsuccessful and/or
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short-lasting (9). There is thus an urgent need to develop novel
therapeutic interventions for this vulnerable population.
Dysfunction in the cerebellar region and its connected
neural networks is thought to be the proximal root cause of
movement disorder in patients with SCA (1, 2, 10). Therapeutic
strategies aimed at functional improvement of the cerebellum
may thus lead to significant clinical benefit within this vulnerable
population. Repetitive transcranial magnetic stimulation (rTMS)
enables non-invasive modulation of cortical excitability (11).
rTMS targeting cerebellar structures is capable of inducing
long-lasting changes in the excitability of cerebello-thalamo-
cortical pathways (12–14). Shiga et al. (15) reported that as
compared to a sham intervention, 21 daily sessions of rTMS
targeting the cerebellum improved performance in several short
clinical tests of gait and posture, when tested immediately after
the intervention was completed, in a cohort of patients with
spinocerebellar degeneration. Still, the longer-term effects of
rTMS on the clinical impression of symptom severity, as well
as the biomechanical control of gait and standing posture,
have not been established. We therefore conducted a small, yet
well-controlled trial to assess the effects of a four-week, 20-
session rTMS intervention targeting the cerebellum, as guided by
individual brain anatomy using structural MRI, on the clinical
severity of SCA and the control of standing posture and gait
using quantitative kinematic assessments, in patients with SCA
as confirmed by genetic testing.
METHODS
Trial Design
A parallel-group, randomized controlled trial was conducted
(NCT01975909). Enrolled participants completed baseline
assessments and a structural brain MRI. They were then assigned
to receive the rTMS or sham intervention via permuted block
randomization with stratification by sex. rTMS was administered
by study personnel uninvolved in other study procedures.
Participants and the study staff who assessed outcomes were
blinded to intervention arm. Immediate (i.e., within 1 week of
intervention completion) and 1-month follow-up assessments
were completed.
Trial Registration
This study was registered prospectively at https://clinicaltrials.
gov/ (NCT01975909).
Participants
Participants were recruited between 2013 and 2015 from the
Neurogenetics Clinic and Movement Disorders Center at the
Beth Israel Deaconess Medical Center (BIDMC), local ataxia
support organizations, the National Ataxia Foundation and
clinicaltrials.gov.
Inclusion criteria included SCA confirmed by genetic testing,
age 18–75, the ability to ambulate without assistance from
another person (canes/walkers allowed), a score >3 on the
“gait” subsection of the Scale for the Assessment and Rating
of Ataxia (SARA) (16), a negative pregnancy test and stable
medications. Exclusion criteria were unstable neurological illness
or concomitant medical condition (i.e., stroke, arthritis, etc.),
clinically-significant abnormalities on screening (e.g., basic lab
work or EKG abnormalities), concurrent participation in another
clinical study, history of substance abuse, untreated depression,
dementia, psychiatric illness, subjects who were wheelchair
bound, Mini Mental Status Exam score <24, legal incapacity
or limited legal capacity. TMS and MRI-specific exclusions
included metal in the head, history of neurosurgical procedures,
ferromagnetic bioimplants, metallic paint, history of seizure
disorder, claustrophobia, current usage of buproprion or other
medications that may increase risk of TMS-induced seizures.
We screened 110 individuals. Seventy-nine were ineligible and
11 were uninterested (Figure 1). The remaining 20 completed
baseline testing. Ten were randomized to the rTMS intervention
(women = 8; SCA type 3 = 8; mean ± SD age = 53 ± 9 years;
height = 164 ± 10 cm; body mass = 71 ± 13 kg) and ten to
sham (women = 8; SCA type 3 = 6; age = 49 ± 4 years; height
= 161 ± 6 cm; body mass = 67 ± 13 kg). All 20 participants
were naïve to TMS and completed the intervention and all
study assessments.
Intervention
The rTMS intervention comprised 20 sessions over 4 consecutive
weeks. A Magstim 200 (UK) and 14 cm circular coil delivered
stimuli at 100% of maximal stimulator output intensity with the
coil centered over three regions: the inion, 4 cm lateral to the left
of the inion, 4 cm lateral to the right of the inion. Participants
were asked to lay their head down on a pillow placed on a
table in front of them, and the handle of the TMS coil was held
facing upwards. Structural MRIs were used to locate and mark
each region for rTMS and neuronavigation using Brainsight R©
(Rogue Resolutions, Cardiff, Wales) ensured that all stimuli for
a given region within and across daily sessions targeted the
same cerebellar regions. For each region, five pulses separated
by 6 s were delivered counter-clockwise, followed by five pulses
delivered clockwise, for a total of 10 pulses per region and session,
and a total of 30 pulses per session (15). For sham intervention,
the same parameters and procedures were used except the coil
was angled 90 degrees from the scalp, inducing non-measurable
changes of the excitability in cerebellum (17).
Ethics
This study was carried out in accordance with the
recommendations of the BIDMC Institutional Review Board with
written informed consent from all subjects. All participants gave
written informed consent in accordance with the Declaration of
Helsinki. The protocol was approved by the BIDMC Institutional
Review Board.
Assessments
Assessments were conducted at the Harvard-Catalyst Clinical
Research Center at the BIDMC at approximately the same time
of day. Screening included health history, neurological exam, the
Mini Mental State Examination and the SARA. A nurse recorded
medications, resting EKG, vital signs, height and body mass.
Hematology, pregnancy testing (if applicable), renal and liver
panels were completed. A study physician reviewed screening
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FIGURE 1 | Study CONSORT diagram. One hundred and ten individuals were screened. Seventy-nine were ineligible and 11 were uninterested. The remaining 20
completed baseline testing. Ten were randomized to the rTMS intervention and ten to sham. All of them completed the intervention and both follow-ups.
data to determine eligibility. The SARA, nine-hole peg test,
Timed Up-and-Go (TUG) and biomechanical assessments of
standing posture and gait were measured at baseline and at both
follow-ups. Assistive devices were allowed on all tests except
standing posture.
Scale for the Assessment and Rating of
Ataxia (SARA)
The clinical severity of SCA was measured using the valid and
reliable SARA scoring scale (16). This scale consists of eight
items related to gait, stance, sitting, speech, finger-chase test,
nose-finger test, fast alternating movements, and heel-shin test.
9-Hole Peg Test
The peg test was used to assess fine motor control hand and
manual dexterity (18). Participants were asked to remove the pegs
from the holes, one by one, and then replace them back into
the container. The time to complete the test was recorded, with
longer times reflecting worse performance.
Timed Up-and-Go Test (TUG)
The TUG test was used to assess functional mobility (19).
The time taken to stand from a chair, walk forward three
meters, turn around, walk back, and return to a seated position
was recorded.
Assessment of Standing Posture and Gait
Standing postural control and gait were assessed using standard
procedures. Postural control was assessed by measuring postural
sway (i.e., center of pressure) fluctuations (240Hz) during
standing on a stationary force platform (AMTI, Watertown,
MA). Participants were asked to stand barefoot on the platform
and complete two 30-s trials under both eyes-open and eyes-
closed conditions. Trial order was randomized. Tissue paper
was placed on the force platform and foot placement of each
participant was outlined prior to the first trial. This outline was
then used throughout all future assessments and trials to ensure
consistent foot placement over time. Participants were instructed
to “stand as still as possible” prior to each trial. For eyes-open
trials, participants were further instructed to visually focus on a
target “X” placed on the wall approximately 3-m in front of them
at eye-level.
Gait was assessed by measuring the kinematics of walking
using the wireless Mobility Lab R© system (APDM, Seattle WA)
during a 90-s walk. Participants were instructed to walk at
their normal, preferred paced. The use of assistive device (e.g.,
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cane) was allowed and if it was used, the same device was used
throughout the study.
Study Outcomes
The primary outcome of this study was the SARA total
score. Secondary outcomes included performance within clinical
functional tests (9-hole peg test, TUG) and metrics related to
standing postural control and gait. Standing postural control
metrics were chosen based upon their sensitivity to change in
SCA severity (3) and included average sway speed (i.e., center-
of-pressure path length divided by trial duration) and area (i.e.,
the area of a confidence ellipse enclosing 95% of the center-
of-pressure trajectory) during both eyes-open and eyes-closed
conditions. Gait metrics included average walking speed, stride
time variability (i.e., the coefficient of variation about the mean
between consecutive heel strikes of the right foot) and double
support time (i.e., the average percentage of each stride time spent
with both feet on ground), as each has been linked to SCA severity
and related functional decline (4, 5).
Statistical Analysis
Analyses were performed using JMP Pro 12 (SAS Institute, Cary,
NC). Descriptive statistics summarized group demographics
and outcomes. Potential between-group differences in baseline
characteristics were tested with Student’s t-tests or chi-square
tests. Primary analyses examined the effects of rTMS on primary
and secondary outcomes using two-way repeated-measures
ANOVAs. As groups differed in several measures of functional
performance at baseline, dependent variables were the percent
change in each outcome from baseline to each follow-up visit.
Model effects included follow-up time (within-subject: one-
week, one-month), group (between-subject: rTMS, sham), and
their interaction. Models were completed with and without
adjustments for age, sex, and intervention compliance. Two
secondary analyses were complete based upon the observed
effects of rTMS intervention on SARA performance. First, as a
potential placebo effect was observed in SARA total score at the
one-week follow-up, a one-way repeated-measures ANOVA was
completed to determine the between-subject effect of group on
the percent change in SARA total score only from baseline to
the 1-month follow-up visit. Second, similar two-way models
as described above were completed to examine the effects of
intervention on each of the nine SARA items. Significance level
for all statistical tests within this pilot study was set to p < 0.05.
Effect sizes of significant models was measured using Cohen’s d
and the partial eta square metric (η2).
Sample size considerations: To our knowledge, this was the
first pilot study to systematically test the effects of MRI-
guided cerebellar rTMS on the SARA and other functional and
biomechanics outcomes over a 1-month follow-up period in
patients with genetically-confirmed SCA. While the primary
objective of this study was to provide the data needed to
appropriately power more definitive trials in the future, we
conducted a priori sample size calculations based upon Shiga
et al. (15). That study reported the immediate after-effects of a
non-MRI-guided, 21-day cerebellar rTMS intervention on 10-
m walking speed in 74 patients with suspected SCA. The rTMS
group decreased their 10-m walk time (from 14.3 ± 1.8 to 9.9
± 0.7 s, mean ± SD) significantly more than those receiving the
sham treatment (from 13.7 ± 1.2 to 13.6 ± 1.2 s). We estimated
that a sample size of 20 would provide over 80% power to detect
a similar effect size, after adjusting for three covariates.
RESULTS
The demographic, SCA and health characteristics of each
participant are listed in Table 1. The groups receiving rTMS
and sham intervention had similar age, height and body mass.
At baseline, the rTMS group, as compared to the sham group,
exhibited lower SARA scores (p = 0.01), faster 9-hole peg test
time (p = 0.03) and faster postural sway speed during eyes-open
standing (p = 0.01) (Table 2). No other between-group baseline
differences were observed. Baseline functional outcomes did not
differ by sex (p > 0.56) and were not significantly correlated
with participant age (p > 0.33) or BMI (p > 0.40). Intervention
compliance was high (19± 2 of 20 sessions) and similar between
groups. The rTMS and sham interventions were well-tolerated
and no unexpected side effects or adverse events were reported.
Primary and secondary outcomes are presented by
intervention group in Table 2. A two-way, repeated-measures
ANOVA revealed a trend toward a main effect of group for SARA
total score (F = 2.0, p = 0.16, Cohen’s d = 0.5, η2 = 0.06). As
can be observed in Figure 2A, both groups exhibited relatively
large percent reductions (i.e., improvements) in this outcome
from baseline to the immediate follow-up. Secondary analyses
omitting the one-week follow-up assessment revealed that the
rTMS intervention, as compared to sham, induced a greater
percent decrease in SARA total scores from baseline to the
1-month follow-up (F = 9.3, p = 0.008, Cohen’s d = 1.3, η2
= 0.38) (Figure 2A). This effect was independent of age, sex,
and intervention compliance. Spurred by this observation, the
effects of intervention on the percent change from baseline to the
1-month follow-up in each of the nine SARA sub-scores were
also examined. rTMS, compared to sham, improved performance
within the “stance” sub-score (F = 10.4, p = 0.002, Cohen’s d
= 0.9; η2 = 0.24) (Figure 2B). No other item-specific changes
within the SARA exam were observed between groups.
The beneficial effect of rTMS on the clinical assessment
of posture was corroborated by improvements within several
objective kinematic metrics of standing postural sway. As
compared to sham, those who completed the rTMS intervention
exhibited a greater percent decrease in postural sway speed when
standing with eyes open (group effect: F= 9.5, p= 0.004, Cohen’s
d = 1.0; η2 = 0.28) and eyes closed (group effect: F = 11.4,
p = 0.002, Cohen’s d = 1.0, η2 = 0.26) (Figures 2C,D). rTMS,
as compared to sham, also reduced sway area during eyes-closed
standing (F = 8.5, p = 0.007, Cohen’s d = 0.9, η2 = 0.17). Each
of these observed group effects were independent of age, sex, and
intervention compliance. No main effects of time, nor group by
time interactions, were observed for any metric.
Participant-level results of intervention on postural sway
speed are presented in Figure 3. Seven of ten participants who
received rTMS exhibited slower sway speed (i.e., better standing
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TABLE 1 | Demographics and baseline functional performance of each participant.
Participant ID Age (years) Sex BMI SCA-type rTMS SARA 9-hole peg test (s) TUG time (s)
P001 61 Male 29.3 3 Real 22.5 78.0 65.0
P002 52 Female 21.7 3 Sham 13.5 39.5 22.1
P003 45 Female 25.8 3 Sham 24 45.8 68.8
P004 45 Female 21.9 3 Sham 15.5 51.7 49.7
P005 47 Male 27.1 1 Sham 13.5 41.8 20.4
P006 38 Male 19.8 3 Real 10 34.8 42.6
P007 47 Male 24.5 3 Sham 24.5 76.9 119.9
P008 52 Male 27.3 3 Real 14 37.2 24.4
P009 44 Female 28.3 3 Real 11 32.4 21.2
P010 54 Female 18.1 6 Sham 19.5 61.0 51.3
P011 65 Female 30.2 3 Real 14.5 40.5 39.3
P012 47 Female 29.3 2 Sham 19 55.2 33.5
P013 54 Female 28.7 3 Real 16.5 28.6 36.0
P014 56 Female 32.9 8 Sham 12 29.9 31.3
P015 46 Female 22.5 3 Sham 16 37.9 35.3
P016 49 Female 20.1 3 Real 15 30.4 24.9
P017 49 Female 32.3 14 Sham 13.5 18.3 20.6
P018 50 Male 25.6 6 Real 13 27.7 18.8
P019 47 Female 22.9 3 Real 11 21.1 14.3
P020 68 Female 25.6 6 Real 18.5 32.4 18.8










SARA (total) 13.7 ± 2.8 10.7 ± 3.4 9.8 ± 2.6 17.1 ± 4.5 12.9 ± 4.9 14.7 ± 4.0
TUG 26.7 ± 10.1 22.5 ± 7.8 20.2 ± 5.6 32.0 ± 16.6 30.5 ± 11.6 31.5 ± 13.9
9-hole peg test (sec) 31.6 ± 5.7 30.6 ± 5.6 30.8 ± 5.4 42.3 ± 13.1 42.3 ± 14.3 41.0 ± 13.5
POSTURAL SWAY
Eyes-open
Speed (mm/s) 41.2 ± 15.9 27.0 ± 10.2 24.8 ± 10.7 21.5 ± 9.0 20.3 ± 8.9 22.9 ± 7.1
Area (mm2 ) 639 ± 376 467 ± 228 436 ± 173 602 ± 636 479 ± 303 674 ± 249
Eyes-closed
Speed (mm/s) 81.4 ± 46.5 51.0 ± 24.3 55.0 ± 30.0 61.0 ± 17.1 63.0 ± 40.4 68.4 ± 40.3
Area (mm2 ) 1992 ± 1337 824 ± 404 1303 ± 839 868 ± 780 1156 ± 938 1517 ± 1382
GAIT
Speed (m/s) 1.0 ± 0.3 1.0 ± 0.4 1.0 ± 0.4 0.9 ± 0.4 0.9 ± 0.4 0.9 ± 0.4
Variability (%) 7.0 ± 3.3 5.9 ± 2.3 5.6 ± 3.8 8.0 ± 5.8 7.8 ± 6.2 8.3 ± 5.9
Double support (%) 27.9 ± 6.9 25.2 ± 7.8 24.2 ± 11.3 27.6 ± 15.2 30.0 ± 14.2 31.2 ± 14.5
SCA, spinocerebellar ataxia; rTMS, repetitive transcranial direct current stimulation; SARA, scale for the assessment and rating of ataxia; TUG, Timed Up-and-Go.
postural control) during eyes-open standing at the 1-month
follow-up assessment as compared to baseline. In contrast, only
two sham participants demonstrated such improvements. Nine
rTMS participants exhibited slower sway speed during eyes-
closed standing 1 month following the intervention, as compared
to only three sham participants.
rTMS did not have significant effects on performance within
the 9-hole peg test, the TUG test of mobility, or on metrics of gait
performance (i.e., walking speed, stride time variability, double
support time).
DISCUSSION
This randomized sham-controlled pilot clinical trial provided
preliminary evidence that cerebellar rTMS intervention is safe
and feasible for patients with SCA who vary considerably in
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FIGURE 2 | The effects of cerebellar rTMS on the clinical assessment of ataxia and standing postural control (mean ± SE). Both groups exhibited relatively-large
improvement (i.e., percent reduction) in SARA total score from baseline to the immediate follow-up (A). The rTMS group, however, exhibited greater percent
improvement in this outcome, as compared to the sham group, at the 1-month follow-up. Secondary analyses revealed that compared to sham, the rTMS group
exhibited greater improvements specifically within the SARA “stance” sub-score (B), yet no other SARA item (outcomes not pictured). Moreover, rTMS improved
postural sway speed (i.e., sway speed decreased) during both eyes-open (C) and eyes-closed (D) standing. *Indicates significant main effects of group within
two-way, repeated-measures ANCOVAs adjusted for age, sex, and intervention compliance.
age and disease progression. Participants who completed the
4-week rTMS intervention exhibited significant improvements
to both clinical and kinematic outcomes of standing postural
control, over a 1-month follow-up period, as compared to those
who received the sham intervention. rTMS did not influence
manual dexterity, functional mobility or gait kinematics during
the follow-up period. Still, the potential benefits of rTMS on
posture warrant larger, more definitive trials to establish the
effects of MRI-guided cerebellar rTMS on postural control, as
well as activities of daily living and quality of life in SCA.
rTMS intervention improved the clinical impression of
standing posture (i.e., the SARA “stance” sub-score), along with
multiple metrics of postural sway when standing with eyes
open and closed. In each case, the value of Cohen’s d was
greater than 0.8, indicating a large effect size of intervention on
this important functional domain. These results are supported
by Shiga et al. (15), who reported that an rTMS intervention
targeting the cerebellum improved the capacity to stand with
different bases of support (i.e., foot placements), when tested
soon after completion of the intervention. The current results
further suggest that rTMS may enhance standing balance by
improving the capacity to control (i.e., minimize) the speed
and magnitude of postural sway, and that such improvements
may persist for at least 1 month. Future large-scale studies
are thus needed to confirm these results, and, to establish the
mechanisms through which cerebellar stimulation may improve
standing posture. The regulation of posture when standing relies
upon a complex control system that utilizes and integrates
multiple sources of sensory input within spinal and supra-spinal
networks to generate both automatic and volitional corrective
muscular actions (20–22). Neuroimaging studies indicate that the
task of standing, as compared to sitting, activates a distributed
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FIGURE 3 | Individual effects of cerebellar rTMS intervention on standing postural control. The average speed of standing postural sway fluctuations for each
participant when standing with eyes open (top) and eyes closed (bottom) at baseline and at the immediate and 1-month follow-up assessments. Two participants
with extremely high sway speed values at baseline (out of the mean ± 2XS.D.) were excluded from the figure for better visual effects.
network of brain regions including the cerebellum, primary
motor cortex, and other regions involved in sensory integration
and/or cognitive-motor control (22, 23). SCA causes postural
disturbances, at least in part, by impairing functional activation
of cerebellar Purkinje cells. This in turn inhibits cortical motor
activation via a complex neural pathway involving the dentate
nucleus (10). Several recent studies have demonstrated that
cerebellar rTMS is capable of facilitatingmotor cortical activation
via modulation of Purkinje cell excitability (24–26). Future
studies employing paired-pulse TMS methodology are thus
needed to examine the effects of cerebellar rTMS intervention
on motor cortex excitability, and its links to postural control, in
those individuals with SCA.
Both the rTMS and sham groups demonstrated improved
performance in the SARA total score at the immediate follow-
up assessment, as compared to baseline (Figure 2A). However,
within the sham group, this initial improvement was attenuated
at the 1-month follow-up assessment. This short-lasting positive
effect of rTMS in the sham group was only present for the
SARA total score, and may have reflected a placebo effect
of the intervention. Such placebo effects have been reported
in several other studies in those with cerebellar degeneration
(27, 28). For example, in a multi-center study of patients with
cerebellar ataxia, ondansetron and placebo interventions resulted
in a similar improvement in performance on the International
Cooperative Ataxia Rating Scale (ICARS) over the follow-up
period (27). Additionally, in the current study, a proportion
of participants within each intervention arm stayed within the
hospital’s Clinical Research Center for the duration of the study
and thus received ongoing clinical research staff supervision
that was likely greater than their normal care. The possibility
that this increased attention confounded the initial effects of
intervention, together with the potential for a significant placebo
effect within this population, are thus important factors to
consider when designing future trials of rTMS or other therapies
in SCA.
While the effects of rTMS on outcomes related to postural
control were independent of age, sex, and intervention
compliance, the small sample size of this pilot study limited
our capacity to statistically control for additional, important
covariates such as SCA subtype. Considerable between-subject
variance in symptom severity and functional status was present,
and despite random assignment to intervention arm, the rTMS
group exhibited better functional performance at baseline.
Nevertheless, the observations that the rTMS intervention was
well-attended and not associated with any unexpected side
effects or adverse events, together with preliminary evidence
of improved postural control, highlight the potential for this
form of non-invasive brain stimulation to serve as a therapeutic
rehabilitative strategy for SCA.
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